Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Visen Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon PTH

            Therapeutic Area: Endocrinology Product Name: TransCon PTH

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Ascendis Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2021

            Details:

            The multicenter, randomized, open-label and parallel control study aims to demonstrate noninferiority in annualized height velocity following weekly injections of TransCon hGH compared to once daily dosing of hGH after 52 weeks of treatment in prepubertal children with GHD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon hGH

            Therapeutic Area: Endocrinology Product Name: TransCon hGH

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Sequoia China

            Deal Size: $150.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 09, 2021

            Details:

            Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TransCon CNP

            Therapeutic Area: Genetic Disease Product Name: TransCon CNP

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved VISEN's IND application to conduct a phase 2 clinical trial of TransCon TM C-Type Natriuretic Peptide (CNP) for patients with achondroplasia (ACH).